Company Monitoring Page for AstraZeneca

latest headlines for company on cafepharma

AstraZeneca follows rival Boehringer in capping out-of-pocket costs for inhalers
Reuters
Mon, 03/18/24 - 11:05 am
Tags:
AstraZeneca, inhalers, drug pricing, Boehringer Ingelheim, Airsupra, Bevespi Aerosphere, Breztri Aerosphere, COPD
AstraZeneca boosts rare disease portfolio with $1.05B Amolyt acquisition
BioSpace
Thu, 03/14/24 - 11:38 am
Tags:
AstraZeneca, M&A, Amolyt Pharma, eneboparatide, hypoparathyroidism
AstraZeneca kick-starts Phase III COPD trial for Breztri
Clinical Trials Arena
Thu, 03/14/24 - 11:21 am
Tags:
AstraZeneca, COPD, clinical trials, Breztri
RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter
Stat
Thu, 03/7/24 - 05:35 pm
Tags:
Sanofi, AstraZeneca, Beyfortus, RSV, monoclonal antibodies
AstraZeneca to invest 650 million pounds in UK to boost 'pandemic preparedness'
Reuters
Wed, 03/6/24 - 11:18 am
Tags:
AstraZeneca, pandemic, UK
Surprise Enhertu rejection follows NICE process change
Pharmaphorum
Tue, 03/5/24 - 11:35 am
Tags:
AstraZeneca, Daiichi Sankyo, HER2-low breast cancer, Enhertu, NICE, UK
AstraZeneca’s drug pricing lawsuit dismissed by federal judge
BioPharma Dive
Mon, 03/4/24 - 11:46 pm
Tags:
AstraZeneca, drug pricing, legal, Medicare, Inflation Reduction Act
ADC Market Will Remain Hot in Oncology, Reaching $30B by 2028: Report
BioSpace
Fri, 03/1/24 - 11:52 am
Tags:
oncology, cancer, antibody-drug conjugate, Merck, AbbVie, Pfizer, AstraZeneca
AstraZeneca finally drops roxadustat US rights after FDA rejection, trial failure
Fierce Pharma
Tue, 02/27/24 - 11:16 am
Tags:
AstraZeneca, FibroGen, roxadustat, anemia
6 first-half 2024 oncology data readouts to watch
BioSpace
Mon, 02/26/24 - 11:20 am
Tags:
oncology, clinical trials, Daiichi Sankyo, AstraZeneca, Enhertu, metastatic breast cancer, Gilead Sciences, Trodelvy, bladder cancer, GSK, Zejula, Jemperli, ovarian cancer, Roche, tiragolumab, Tecentriq, non-small cell lung cancer, Cue Biopharma, CUE-101, head and neck cancer, Elicio Therapeutics, ELI-002, solid tumors
What did Big Pharma CEOs get paid in 2023?
Medical Marketing and Media
Fri, 02/23/24 - 10:22 am
Tags:
Pharma CEOs, executive pay, AstraZeneca, Roche, Novartis
Daiichi Sankyo and AstraZeneca’s lung cancer antibody set for FDA review
Clinical Trials Arena
Tue, 02/20/24 - 11:30 am
Tags:
Daiichi Sankyo, AstraZeneca, FDA, Tagrisso, non-small cell lung cancer
AstraZeneca’s Evusheld fails to improve Covid outcomes in Phase III trial
Clinical Trials Arena
Tue, 02/20/24 - 11:01 am
Tags:
AstraZeneca, Evusheld, clinical trials, COVID-19
FDA approves AstraZeneca's Tagrisso-chemo combo
Reuters
Sun, 02/18/24 - 08:26 pm
Tags:
AstraZeneca, Tagrisso, lung cancer, FDA
COVID-19 Cliff and Skyrocketing GLP-1 Drug Sales Highlight Q4 2023 Earnings
BioSpace
Sun, 02/11/24 - 03:50 pm
Tags:
earnings, COVID-19, GLP-1 agonist, JNJ, Bristol Myers Squibb, Pfizer, AstraZeneca, Sanofi, Eli Lilly, Novo Nordisk
AstraZeneca’s year-end revenues rise but Wall Street remains unimpressed
Medical Marketing and Media
Thu, 02/8/24 - 11:23 am
Tags:
AstraZeneca, earnings, COVID-19
AstraZeneca to invest $300 million in US facility for cell therapies
Reuters
Tue, 02/6/24 - 11:38 pm
Tags:
AstraZeneca, cell therapy
AstraZeneca's phase 3 heart disease trial hits, teeing up Pfizer showdown in Japan
Fierce Biotech
Fri, 02/2/24 - 11:53 am
Tags:
AstraZeneca, Pfizer, acoramidis, Japan, clinical trials, cardiomyopathy, ATTR-CM
AstraZeneca Case Leads Off Busy Year of Challenges to Medicare Drug Pricing Law
BioSpace
Thu, 02/1/24 - 10:51 pm
Tags:
AstraZeneca, legal, Inflattion Reduction Act, Medicare, drug pricing
Sanofi expects RSV antibody to ⁠breach blockbuster status in 2024, even as supply hitch drags on
Fierce Pharma
Thu, 02/1/24 - 11:33 am
Tags:
Sanofi, RSV, AstraZeneca, Beyfortus

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.